# Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

> **NCT04124731** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 98 (estimated)

## Conditions studied

- Carcinoma
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** sintilimab plus anlotinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04124731
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10
- **Primary completion:** 2021-04
- **Final completion:** 2022-04
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2019-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04124731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04124731, "Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04124731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*